NCT01121276View on ClinicalTrials.gov

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

82

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

DRUG

Faster-acting insulin aspart

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

insulin aspart

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

Faster-acting insulin aspart

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

Faster-acting insulin aspart

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

Faster-acting insulin aspart

0.2 U/kg body weight injected subcutaneously (under the skin)

Trial Locations (1)

91911

Novo Nordisk Investigational Site, Chula Vista

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY